Mode
Text Size
Log in / Sign up

Systematic review of Mycobacterium riyadhense infection in 69 cases shows common presentations and drug susceptibility patternsA rare infection hits lungs and bones: what doctors need to know about treating Mycobacterium riyadhense

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider susceptibility to rifampin and ethambutol but resistance to isoniazid in M. riyadhense infections.

This systematic review and meta-analysis examined Mycobacterium riyadhense infection in 69 cases, including both immunocompetent and immunocompromised patients. The study compiled data from various sources to describe clinical presentations and drug susceptibility patterns, without a specific intervention or comparator group. The median patient age was 35.5 years, with 80% male gender proportion, though the setting and follow-up details were not reported.

Main results indicated that pneumonia was the most common presentation, occurring in 52 cases, followed by lymphadenitis in 13 cases, osteomyelitis in 8 cases, and disseminated infection in 8 cases. Regarding drug susceptibility, all tested isolates were susceptible to rifampin and ethambutol, while resistance to isoniazid was detected in 5 out of 8 isolates. No effect sizes, p-values, or confidence intervals were provided for these outcomes.

Safety and tolerability data were not reported in the input. Key limitations include significant variability in the diagnosis and treatment of M. riyadhense across the included cases, which may affect the generalizability and reliability of the findings. The practice relevance underscores the urgent need for standardized diagnostic protocols and targeted treatment strategies to effectively manage these infections, but this is based on observational evidence without causal implications.

Imagine a germ that hides in the lungs, bones, and lymph nodes, causing serious trouble for both healthy people and those with weak immune systems. A recent look at 69 cases found that pneumonia was the most common sign, followed by infections in the lymph nodes, bones, and spread throughout the body. The average patient was a young man around 35 years old.

When doctors tested the germs, most were sensitive to common medicines like Rifampin and Ethambutol. However, a worrying pattern emerged: five out of eight tested germs were resistant to Isoniazid, a drug often used to fight similar infections. This suggests that relying on standard recipes might not always work for this specific bug.

The study highlights a major problem: there is no single agreed-upon way to diagnose or treat this infection. Because the medical community has not standardized how to handle these cases, patients risk getting the wrong medicine or a delayed diagnosis. Until doctors agree on better protocols, managing this rare but dangerous infection remains a challenge.

What this means for you:
Standard drugs often work, but half the germs resist Isoniazid, so doctors need clear rules for diagnosing and treating this rare infection.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
BackgroundMycobacterium riyadhense is an emerging nontuberculous mycobacterium associated with infections in immunocompetent and immunocompromised patients.MethodsTo identify the epidemiology, risk factors, presentations, and antimicrobial susceptibility of M. riyadhense, we conducted a systematic review on PubMed, Web of Science, and Google Scholar adhering to PRISMA guidelines. We included publications during 2009-2025, with no limitation on language or study design. Cases of uncertain infection or identification were excluded. Review protocol was pre-registere in PROSPERO with protocol number; CRD420250653025.ResultsWe identified 22 studies reporting on 69 cases of M. riyadhense. Patient median age was 35.5 and 80% were male. Common presentations included pneumonia (n=52), lymphadenitis (n=13), osteomyelitis (n=8), or disseminated infection (n=8). Susceptibility to Rifampin and Ethambutol was observed in all tested isolates. Resistance to Isoniazid was detected in 5/8 isolates.ConclusionThis review identified a significant variability in the diagnosis and treatment of M. riyadhense. This underscores the urgent need for standardized diagnostic protocols and targeted treatment strategies to effectively manage infections.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD420250653025.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.